Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.

INTRODUCTION

Paxlovid (nirmatrelvir/ritonavir) is a new oral antiviral drug that is used for coronavirus disease 2019 (COVID-19) and is administered to patients with mild to moderate disease for five consecutive days. This meta-analysis aimed to evaluate the efficacy of Paxlovid in COVID-19 patients.

METHODOLOGY

PubMed, Embase, Cochrane Library, and Web of Science databases were searched to identify relevant publications up to 9 March 2023. Three randomized controlled trial (RCT) studies, one prospective cohort study, and 25 retrospective cohort studies were identified for the meta-analysis.

RESULTS

There was a significant difference between the Paxlovid and control groups in terms of hospitalization (RR = 0.53; 95% CI: 0.24-0.69, p < 0.001), all-cause mortality (RR = 0.36; 95% CI: 0.27-0.50, p < 0.001), hospitalization or death (RR = 0.50; 95% CI: 0.37-0.67, p < 0.001), intensive care unit admission (RR = 0.45; 95% CI: 0.27-0.73, p = 0.001), and emergency department visits (RR = 0.67; 95% CI: 0.54-0.83, p < 0.001). However, no significant difference was found between the two groups in terms of COVID-19 rebound (OR = 1.18; 95% CI: 0.82-1.68, p = 0.37). In addition, the Paxlovid group had a significantly shorter hospital length of stay (weighted mean difference WMD = -1.11; 95% CI, -1.81, -0.41; I2 > 50%, p < 0.05), and polymerase chain reaction negative conversion time (WMD = -2.75; 95% CI, -3.60, -1.89, I2 > 50%, p < 0.05) than that of the control group.

CONCLUSIONS

Paxlovid can be considered an effective therapeutic agent for treating patients with COVID-19.